-
Mashup Score: 4
— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years — — JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 19
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
Amazing! Are we heading toward cure of type I #diabetes? @AliceYYCheng @AmarPut @GoggleDocs #CardioTwitter #MedTwitter https://t.co/uwgFBSUwnG
-
-
Mashup Score: 19
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
Amazing! Are we heading toward cure of type I #diabetes? @AliceYYCheng @AmarPut @GoggleDocs #CardioTwitter #MedTwitter https://t.co/uwgFBSUwnG
-
-
Mashup Score: 19
– All 12 patients who received the full dose of VX-880 as a single infusion demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90 – – All patients achieved ADA -recommended target HbA1c levels 70% time-in-range (70-180 mg/dL), and 11 of 12 patients…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
Amazing! Are we heading toward cure of type I #diabetes? @AliceYYCheng @AmarPut @GoggleDocs #CardioTwitter #MedTwitter https://t.co/uwgFBSUwnG
-
-
Mashup Score: 1
– ADPKD is the most common inherited kidney disease, with no treatments currently available that address the underlying cause of disease – – Vertex to initiate a Phase 1 clinical trial in healthy volunteers this month – – ADPKD is Vertex’s 10th disease area in the clinic, further expanding the…
Source: news.vrtx.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/xCsrQZN0EJ
-
-
Mashup Score: 3
– Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment – LONDON –(BUSINESS WIRE)–Feb. 13, 2024– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
RT @adamfeuerstein: Casgevy approved in Europe to treat sickle cell disease and beta thalassemia. $VRTX $CRSP https://t.co/5X6jWaigGM
-
-
Mashup Score: 3
– Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment – LONDON –(BUSINESS WIRE)–Feb. 13, 2024– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
RT @adamfeuerstein: Casgevy approved in Europe to treat sickle cell disease and beta thalassemia. $VRTX $CRSP https://t.co/5X6jWaigGM
-
-
Mashup Score: 3
– Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment – LONDON –(BUSINESS WIRE)–Feb. 13, 2024– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has…
Source: news.vrtx.comCategories: General Medicine News, CardiologistsTweet-
RT @adamfeuerstein: Casgevy approved in Europe to treat sickle cell disease and beta thalassemia. $VRTX $CRSP https://t.co/5X6jWaigGM
-
-
Mashup Score: 7
– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure – – Safety profile generally consistent with myeloablative conditioning and autologous stem cell transplant – BOSTON & ZUG,…
Source: news.vrtx.comCategories: Cardiologists, Latest HeadlinesTweet-
Auto ex vivo CRISPR gene editing w up to 3y follow-up. 42/44 transfusion-dependent beta-thal now w/o transfusions. 31/31 sickle cell w recurrent vasoocclusive crises now w/o crises. Promising! 🎉🎉 https://t.co/aRaTSIxaN9 @VertexPharma #EHA2022 https://t.co/6eo2myvG0a
-
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain | Vertex Pharmaceuticals Newsroom https://t.co/3Zajdunh4d